한글목차

치매 및 알츠하이머병 치료 세계 시장 규모는 2024년에 121억 7,000만 달러, 2030년에는 176억 2,000만 달러에 이르고, CAGR 6.56%를 보일 것으로 예측됩니다.

세계 인구의 고령화에 따라 알츠하이머병 및 관련 치매의 유병률이 크게 증가함에 따라 보다 효과적인 치료법에 대한 수요가 증가하고 있습니다. 기존에는 콜린에스테라아제 억제제나 NMDA 수용체 길항제와 같은 대증요법이 시장을 주도해왔지만, 신경과학의 새로운 발전으로 인해 질병 변형 치료의 길이 열리고 있습니다. 이러한 새로운 접근법은 베타 아밀로이드 플라크와 타우 단백질의 엉킴과 같은 이 질병의 생물학적 메커니즘을 다루는 것을 목표로 하고 있습니다. 제약회사와 연구기관들은 이 분야에 많은 투자를 하고 있습니다. 개발은 진행 중이지만, 질병의 복잡성과 높은 임상시험 실패율로 인해 이 분야는 지속적인 장애물에 직면하고 있으며, 의약품 개발 및 상업화 노력은 지속적인 과제입니다.

시장 성장 촉진요인

헬스케어 산업의 성장

주요 시장 이슈

높은 치료 및 관리 비용

주요 시장 동향

타우 표적 치료제의 발전

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 치매 및 알츠하이머병 치료 시장에 미치는 영향

제5장 세계의 치매 및 알츠하이머병 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 약제 클래스별(콜린 작동성/콜린에스테라제(ChE) 억제제, 메만틴, 배합약, 기타)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 치매 및 알츠하이머병 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 치매 및 알츠하이머병 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 치매 및 알츠하이머병 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 치매 및 알츠하이머병 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 치매 및 알츠하이머병 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 혼란 : 분쟁, 팬데믹, 무역장벽

제14장 세계의 치매 및 알츠하이머병 치료 시장 : SWOT 분석

제15장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제16장 경쟁 구도

• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer, Inc.
• Ono Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• H. Lundbeck A/S
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Eli Lilly and Company
• Corium, Inc.

제17장 전략적 제안

제18장 회사 소개 및 면책조항

영문목차

The Global Dementia and Alzheimer's Disease Treatment Market was valued at USD 12.17 Billion in 2024 and is projected to reach USD 17.62 Billion by 2030, growing at a CAGR of 6.56%. As global populations age, the prevalence of Alzheimer's disease and related dementias is rising significantly, fueling demand for more effective therapeutic interventions. While the market has traditionally been driven by symptomatic treatments such as cholinesterase inhibitors and NMDA receptor antagonists, new advancements in neuroscience are now paving the way for disease-modifying therapies. These newer approaches aim to address the biological mechanisms of the disease, including beta-amyloid plaques and tau protein tangles. Pharmaceutical companies and research institutions are investing heavily in this direction. Despite the progress, the field faces ongoing hurdles due to the complexity of the disease and the high rate of failure in clinical trials, which continue to challenge drug development and commercialization efforts.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare industry-generating more than USD 4 trillion in annual revenues-serves as a major catalyst for growth in the dementia and Alzheimer's treatment market. Key contributors include pharmaceuticals and biotechnology, which together account for nearly USD 850 billion, and diagnostics and medical technology, generating over USD 400 billion. With improved life expectancy and better access to medical services, healthcare systems are increasingly prioritizing age-related neurodegenerative diseases. This trend is driving investment in research and development focused on Alzheimer's and dementia therapies, and is supported by growing global awareness and demand for effective long-term treatment options.

Key Market Challenges

High Cost of Treatment and Care

The elevated cost of treatment and associated care services represents a key barrier in the dementia and Alzheimer's disease treatment market. The financial strain extends beyond pharmaceutical expenditures, encompassing long-term care, specialized nursing, and daily assistance-all of which are typically not fully covered by public health insurance in many regions. The introduction of innovative disease-modifying therapies, while clinically promising, adds to cost concerns due to their complex production, monitoring requirements, and regulatory demands. These high costs challenge the affordability and accessibility of new treatments, particularly in low- and middle-income countries with constrained healthcare budgets and limited infrastructure for administering advanced therapeutics.

Key Market Trends

Advancement in Tau-Targeted Therapies

An important trend shaping the market is the increasing focus on tau-targeted therapies as an alternative or complement to amyloid-focused treatments. Research has shown that abnormal accumulation of tau proteins, which form neurofibrillary tangles in the brain, is closely associated with cognitive decline in Alzheimer's patients. As traditional therapies targeting amyloid plaques have delivered limited results, pharmaceutical companies are shifting attention toward tau as a therapeutic target. Innovations such as ACI-35-a liposome-based vaccine targeting phosphorylated tau-have shown promising safety and tolerability profiles in clinical trials. The pipeline now includes various modalities like monoclonal antibodies, antisense oligonucleotides, and small molecule inhibitors aimed at mitigating tau pathology. These advancements are expected to drive future breakthroughs in disease-modifying treatments.

Key Market Players

• Merz Pharma GmbH & Co. KGaA
• Novartis AG
• Pfizer, Inc.
• Ono Pharmaceutical Co., Ltd.
• Johnson & Johnson Services, Inc.
• H. Lundbeck A/S
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.
• Eli Lilly and Company
• Corium, Inc.

Report Scope

In this report, the Global Dementia and Alzheimer's Disease Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dementia and Alzheimer's Disease Treatment Market, By Drug Class:

• Cholinergic/ Cholinesterase (ChE) Inhibitors
• Memantine
• Combination Drugs
• Others

Dementia and Alzheimer's Disease Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Dementia and Alzheimer's Disease Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dementia and Alzheimer's Disease Treatment Market.

Available Customizations:

Global Dementia and Alzheimer's Disease Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Dementia and Alzheimer's Disease Treatment Market

5. Global Dementia and Alzheimer's Disease Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine, Combination Drugs, Others)
  • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Dementia and Alzheimer's Disease Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dementia and Alzheimer's Disease Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
  • 6.3.2. Mexico Dementia and Alzheimer's Disease Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
  • 6.3.3. Canada Dementia and Alzheimer's Disease Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel

7. Europe Dementia and Alzheimer's Disease Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
  • 7.3.2. Germany Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
  • 7.3.3. United Kingdom Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
  • 7.3.4. Italy Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Distribution Channel
  • 7.3.5. Spain Dementia and Alzheimer's Disease Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Dementia and Alzheimer's Disease Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
  • 8.3.2. India Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
  • 8.3.3. South Korea Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
  • 8.3.4. Japan Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Distribution Channel
  • 8.3.5. Australia Dementia and Alzheimer's Disease Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Distribution Channel

9. South America Dementia and Alzheimer's Disease Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Dementia and Alzheimer's Disease Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
  • 9.3.2. Argentina Dementia and Alzheimer's Disease Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
  • 9.3.3. Colombia Dementia and Alzheimer's Disease Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Dementia and Alzheimer's Disease Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Distribution Channel
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Dementia and Alzheimer's Disease Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Distribution Channel
  • 10.3.2. Saudi Arabia Dementia and Alzheimer's Disease Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Distribution Channel
  • 10.3.3. UAE Dementia and Alzheimer's Disease Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Dementia and Alzheimer's Disease Treatment Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Merz Pharma GmbH & Co. KGaA
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Novartis AG
• 16.3. Pfizer, Inc.
• 16.4. Ono Pharmaceutical Co., Ltd.
• 16.5. Johnson & Johnson Services, Inc.
• 16.6. H. Lundbeck A/S
• 16.7. F. Hoffmann-La Roche Ltd.
• 16.8. AbbVie Inc.
• 16.9. Eli Lilly and Company
• 16.10. Corium, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer